• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Baird Medical Investment Holdings Ltd

    1/28/25 6:02:03 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care
    Get the next $BDMD alert in real time by email
    6-K 1 tm254530d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of January 2025

    Commission File Number 001-42300

     

    Baird Medical Investment Holdings Limited

     

    Room 202, 2/F, Baide Building, Building 11, No.15
    Rongtong Street, Yuexiu District, Guangzhou,

    Peoples Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F   x  Form 40-F   ¨  

     

     

     

     

     

     

    Change of Auditor

     

    On January 24, 2025, Baird Medical Investment Holdings Limited (the “Company”), upon the approval and ratification of the board of directors of the Company (the “Board”) and the audit committee of the Board (the “Audit Committee”), dismissed Marcum Asia CPAs LLP (“Marcum Asia”), the former independent registered public accounting firm of the Company, effective on January 24, 2025, and appointed Kreit & Chiu CPA LLP (PCAOB ID: 6651) (the “New Auditor”) to serve as its independent registered public accounting firm, effective on January 24, 2025, for the year ended December 31, 2024.

     

    Marcum Asia’s reports on the Company’s financial statements for the fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinion or disclaimers of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

     

    Furthermore, during the fiscal years ended December 31, 2023 and 2022 and through January 24, 2025, there were no disagreements, as defined in Item 16F(a)(1)(iv) of Form 20-F, with Marcum Asia on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum Asia, would have caused Marcum Asia to make reference to the subject matter of the disagreements in connection with its reports on the Company’s financial statements for such year. In addition, during this time, there were no “reportable events,” as defined in as defined in Item 16F(a)(1)(v)(A)-(D) of Form 20-F, except for the material weaknesses related to the Company’s internal control over financial reporting, including (i) lack of sufficient financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and SEC reporting requirements to properly address certain accounting issues and to prepare and review financial statements and related disclosures in accordance with U.S. GAAP and SEC reporting requirements; and (ii) lack of comprehensive accounting policies and procedures manual in accordance with U.S. GAAP and documented controls which enable management and other personnel to understand and carry out their internal control responsibilities.

     

    The Company provided Marcum Asia with a copy of the above disclosure and requested that Marcum Asia furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of Marcum Asia’s letter is filed as Exhibit 16.1 to this Form 6-K.

     

    During the two most recent fiscal years and any subsequent interim periods prior to the engagement of the New Auditor, neither the Company, nor someone on behalf of the Company, has consulted the New Auditor regarding any of the matters described in Item 16F(a)(2)(i) and (ii) of Form 20-F. The New Auditor is aware of the material weaknesses described above and understands it is a reportable event.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Dated: January 28, 2025
         
      By: /s/ Haimei Wu
      Name: Haimei Wu
      Title: Chairwoman and Chief Executive Officer

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit 
    Number
      Description
    16.1   Letter of Marcum Asia CPAs LLP to the U.S. Securities and Exchange Commission dated January 28, 2025

     

     

     

    Get the next $BDMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BDMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Baird Medical Engages Global Clinical Leaders at AAES 2025

      NEW YORK, May 19, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES), taking place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin. The AAES Annual Meeting, a premier academic and clinical forum, convenes leading endocrine surgeons, researchers, and innovators globally to explore advancements in endocrine

      5/19/25 8:30:00 AM ET
      $BDMD
      Medical/Dental Instruments
      Health Care
    • Baird Medical Advances Thyroid MWA Training and Academic Exchange with Leading Harvard Professor

      NEW YORK, May 12, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a leader in Microwave Ablation (MWA) technology, recently hosted an advanced training session and academic exchange in New Orleans, reinforcing its commitment to clinical innovation and research collaboration in minimally invasive thyroid therapies. The program was led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, a leading figure in thyroid ablation and endocrine surgery. He was joined by Dr.

      5/12/25 8:30:00 AM ET
      $BDMD
      Medical/Dental Instruments
      Health Care
    • Baird Medical to Participate in the AAES 2025 Annual Meeting

      NEW YORK, May 6, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES), taking place May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin. The AAES Annual Meeting is widely regarded as the premier gathering of endocrine surgeons in North America, convening leading experts, clinicians, researchers, and trainees in the

      5/6/25 8:30:00 AM ET
      $BDMD
      Medical/Dental Instruments
      Health Care

    $BDMD
    SEC Filings

    See more
    • SEC Form 20-F filed by Baird Medical Investment Holdings Ltd

      20-F - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

      5/15/25 4:17:12 PM ET
      $BDMD
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 20-F filed by Baird Medical Investment Holdings Ltd

      NT 20-F - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

      4/30/25 4:56:28 PM ET
      $BDMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Baird Medical Investment Holdings Ltd

      6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

      1/28/25 6:02:03 AM ET
      $BDMD
      Medical/Dental Instruments
      Health Care